Results 11 to 20 of about 4,153 (212)
Cardiorenal benefits of finerenone: protecting kidney and heart [PDF]
Annals of Medicine, 2023 Albuminuria; Enfermedad renal crónica; FinerenonaAlbuminúria; Malaltia renal crònica; FinerenonaAlbuminuria; Chronic kidney disease; FinerenonePersons with diabetes and chronic kidney disease (CKD) have a high residual risk of developing cardiovascular ...
Facila, Lorenzo +5 more
core +7 more sources
Potassium management with finerenone: Practical aspects
Endocrinology, Diabetes & Metabolism, 2022 Introduction Finerenone, a selective nonsteroidal mineralocorticoid receptor antagonist, has favourable effects on cardiorenal outcomes in patients with mild‐to‐severe chronic kidney disease with increased albuminuria and type 2 diabetes.
Christoph Wanner +6 more
doaj +4 more sources
Patient Counseling for Finerenone [PDF]
Indian Journal Of Clinical Practice, 2023 Finerenone is a nonsteroidal mineralocorticoid receptor antagonist, which is used to retard the progression of chronic kidney disease in persons with type 2 diabetes. This communication describes the various aspects of patient counseling needed to ensure
Banshi Saboo +5 more
core +4 more sources
Optimizing Finerenone Therapy: A Comprehensive Review Using the “Finerenone Pentad” [PDF]
Indian Journal Of Clinical Practice, 2023 Chronic kidney disease (CKD) is a pressing global health concern, often intertwined with comorbid conditions such as type 2diabetes mellitus (T2DM) and cardiovascular complications.
Dr SANJAY KALRA, Dr SOURABH SHARMA
core +4 more sources
Cost-effectiveness of combining finerenone and sodium-glucose cotransporter 2 inhibitors with standard of care for patients with chronic kidney disease and type 2 diabetes in China [PDF]
Renal FailureObjective To evaluate the cost-effectiveness of combining finerenone and Sodium-glucose cotransporter-2 inhibitors (SGLT2i) with standard care (SoC) for Chinese patients with chronic kidney disease (CKD) and type 2 diabetes (T2D).Methods A validated ...
Zhengqiang Hu +3 more
doaj +2 more sources
Mineralocorticoid receptor antagonists: Efficacy and safety in chronic kidney disease. [PDF]
Diabetes Obes MetabAbstract The mineralocorticoid receptor (MR) has a multifaceted role in normal physiologic functions. However, research has uncovered the deleterious consequences of overactivation of the MR. It has been implicated in chronic kidney disease (CKD) via its strong association with glomerulosclerosis, interstitial fibrosis, proteinuria, and decline in ...
Mottl AK, Khunti K, Mathieu C.
europepmc +2 more sources
Cardiovascular Outcomes with Finerenone According to Glycemic Status at Baseline and Prior Treatment with Newer Antidiabetics among Patients with Type 2 Diabetes Mellitus [PDF]
Endocrinology and Metabolism, 2022 Type 2 diabetes mellitus (T2DM) and cardiovascular disease are closely interconnected. We sought to determine the cardioprotective action of finerenone according to prior treatment with newer antidiabetics and glycemic status.
Dimitrios Patoulias +4 more
doaj +1 more source
Metabolism Open, 2023 Background: In the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease trial, finerenone reduced the risk of cardiovascular events in patients with chronic kidney disease (CKD) and type 2 diabetes, while in the ...
Akira Mima +8 more
doaj +1 more source
Diabetic kidney disease, biomarkers, and finerenone. [PDF]
Diabetes Obes MetabAbstract Diabetic kidney disease (DKD), the leading cause of kidney failure worldwide, is associated with an increased risk of cardiovascular disease (CVD). A complex pathobiology involving hemodynamic, metabolic, and immune dysregulation promotes inflammatory and fibrotic pathways that contribute to kidney disease progression and CVD in individuals ...
Verma A, Upadhyay A.
europepmc +2 more sources
Kidney Diseases, 2023 Background: This prespecified subgroup analysis of the FIDELIO-DKD trial aimed to evaluate the efficacy and safety of finerenone in patients with chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM) in China.
Haitao Zhang +13 more
doaj +1 more source